Hengrui Pharma (600276.SH) Financial Statements - Balance Sheet/Income Statement/Cash Flow - Longbridge

Quote List Quote List

Event Tracking

Dec29

Hengrui Medicine Subsidiary Obtains Clinical Trial Approval for HRS-6257

10:01

Dec28

Huahai Pharmaceutical and Shanghai Huahai's SHR-A1904 Injection Listed as Breakthrough Therapy

10:24

Hengrui Medicine Subsidiary Entrusts Hansoh Pharmaceutical for Palocabigine Soft Capsule Commercialization

08:39

Dec24

Hengrui Medicine’s SHR-A1904 Injection Included in Breakthrough Therapy List

08:56

Hengrui Medicine Subsidiary's SHR-A2102 Receives Clinical Trial Approval from NMPA

08:47

Dec21

Five Subsidiaries of Hengrui Medicine Receive Approval for Multiple Drug Clinical Trials

11:04

Schedules & Filings

Schedules

Filings

Oct27

Earning Release(CST)

FY2025 Q3 Earning Release (CNY) Revenue 7.427 B, Net Income 1.301 B, EPS 0.195

Aug20

Earning Release(CST)

FY2025 Q2 Earning Release (CNY) Revenue 8.556 B, Net Income 2.576 B, EPS 0.3982

May23

Distribution Plan(CST)

Cash dividend 0.2 CNY

View More

Stock List

Top Gainers

Top Decliners

Northbound Connect

Symbol

Price

%Chg

Change

View More